Table 3. SF-6D score (at two years), whole blood donations, costs and incremental cost per additional unit of whole blood donated, over two-year follow-up (by gender).
| Male | Female | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Randomised arm | Mean (95% CI) difference | Randomised arm | Mean (95% CI) difference | |||||||
| 8-week (n = 7,417) |
10-week (n = 7,413) |
12-week (n = 7,411) |
8-week vs. 12-week | 10-week vs. 12-week | 12-week (n = 7,549) |
14-week (n = 7,545) |
16-week (n = 7,528) |
12-week vs. 16-week | 14-week vs. 16-week | |
| Mean SF-6D score | 0.84 | 0.84 | 0.84 | 0.002 (-0.002 to 0.006) |
-0.001 (-0.004 to 0.003) |
0.82 | 0.82 | 0.82 | 0.001 (-0.003 to 0.005) |
0.003 (-0.001 to 0.007) |
| Mean whole blood donations ± | 6.89 | 5.98 | 5.19 | 1.71 (1.60 to 1.80) |
0.79 (0.70 to 0.88) |
4.29 | 3.91 | 3.45 | 0.85 (0.78 to 0.92) |
0.46 (0.40 to 0.53) |
| Mean costs (£) ± | 61 | 52 | 45 | 16 (15 to 17) |
7 (6 to 8) |
41 | 37 | 33 | 9 (8 to 9) |
5 (4 to 5) |
| Incremental cost-effectiveness ratio ± | 9.51 (9.33 to 9.69) |
9.00 (8.66 to 9.34) |
10.17 (9.80 to 10.54) |
9.98 (9.32 to 10.64) |
||||||
± The results for whole blood donations are rounded to two decimal places and costs are rounded to no decimal place. The incremental cost-effectiveness ratio results are rounded to two decimal places.